GLP-1 수용체 작용제 및 CGM 융합 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 연결 방식별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)

GLP-1 & CGM Convergence Market Summary

The global GLP-1 & CGM convergence market size was valued at USD 1.6 billion in 2025 and is projected to grow from USD 1.8 billion in 2026 to USD 3.9 billion by 2033, at a CAGR of 11.8% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 84.7% in 2025. The global market is experiencing strong growth, driven by the growing intersection of diabetes, obesity, and metabolic-health management, rising GLP-1 use among type 2 diabetes patients, expanding clinical recognition of CGM beyond insulin-treated populations, and increasing demand for personalized glucose and lifestyle insights.

The 2026 ADA Standards of Care recommend CGM for adults with diabetes where it can aid treatment management, strengthening the clinical relevance of CGM among GLP-1 users. Concurrently, the growing availability of OTC CGM systems is reducing access barriers and expanding use among non-insulin-treated and obesity-focused populations, while greater consumer awareness of real-time glucose responses is positioning CGM as a complementary tool for nutrition, exercise, weight management, and metabolic-health monitoring.

The convergence of GLP-1-based therapies and CGM is gaining momentum as diabetes and obesity management increasingly shift toward integrated, data-driven approaches. GLP-1 receptor agonists and dual GIP/GLP-1 therapies provide pharmacological control of glucose, appetite, and body weight, while CGM provides continuous visibility into glucose patterns, treatment response, and behavioral triggers. The combination, therefore, creates an opportunity to move beyond episodic HbA1c assessment toward continuous, personalized metabolic management. A 2025 review highlighted the potential synergy between GLP-1 therapy and CGM, particularly through CGM-enabled behavioral feedback and individualized monitoring, although randomized evidence in people with obesity without diabetes remains limited.

Recent real-world evidence is strengthening the clinical rationale for combining the two technologies. A prospective study of 264 adults with T2D receiving GLP-1RA therapy who had not achieved their HbA1c target found that adding flash glucose monitoring produced a 0.58 percentage-point reduction in HbA1c versus 0.35 percentage points with GLP-1RA alone over 12 months. Weight reduction was also greater among patients using flash glucose monitoring, at approximately 4.0 kg versus 2.3 kg with GLP-1RA alone.

The findings are particularly relevant because GLP-1 therapy does not eliminate the need for glucose monitoring in patients with diabetes. The 2026 ADA Standards of Care recommend CGM for adults with diabetes on insulin, on non-insulin therapies that can cause hypoglycemia, and on any diabetes treatment where CGM aids management. The guidelines also recognize periodic personal or professional CGM when continuous use is not feasible.

Additional evidence from 2026 further supports the concept of complementary use. A real-world primary-care analysis of 6,169 adults with insulin-treated T2D found that patients receiving both CGM and GLP-1 therapy experienced the largest improvements in HbA1c and body weight compared with either technology/pharmacotherapy alone. At one year, HbA1c declined by 1.70 percentage points with combination therapy, compared with 0.85 points with CGM and 1.16 points with GLP-1 therapy alone. While this population is insulin-treated and therefore represents a more clinically intensive segment, it provides additional evidence that the two interventions can have complementary effects.

From a market perspective, the convergence could accelerate the evolution of CGM from a predominantly glucose-monitoring device into a broader metabolic-management platform. For GLP-1 users with T2D, CGM can provide continuous feedback on glucose response during treatment initiation, dose titration, dietary changes, and lifestyle modification. For GLP-1 users without diabetes, the opportunity is more consumer-oriented: CGM can potentially provide feedback on meals, physical activity, glucose variability, and metabolic responses during weight-management programs. However, this latter opportunity should be considered emerging rather than clinically established, as randomized trials evaluating combined CGM and GLP-1 use specifically in obesity without diabetes are still lacking.

The convergence also creates opportunities for integrated GLP-1 + CGM programs, combining pharmacotherapy with glucose data, nutrition coaching, exercise recommendations, adherence support, and digital health platforms. This could encourage manufacturers and digital-health providers to develop lower-cost, shorter-duration, simplified CGM offerings targeted specifically at GLP-1 users, rather than relying exclusively on traditional long-term CGM models.

Global GLP-1 & CGM Convergence Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global GLP-1 & CGM convergence market report based on product, application, connectivity, distribution channel, and region:

• Product Outlook (Revenue, USD Billion, 2021 - 2033)
• Sensor
• Applicator
• Transmitter
• Device / Reader
• Application Outlook (Revenue, USD Billion, 2021 - 2033)
• Glucose / Diabetes Management
• Lifestyle Monitoring
• Diet & Nutrition Monitoring
• Physical Activity & Fitness Monitoring
• Weight Management
• Connectivity Outlook (Revenue, USD Billion, 2021 - 2033)
• Bluetooth
• 4G / Cellular
• NFC
• Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
• Pharmacies
• E-commerce
• Others
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • Thailand
  • Singapore
  • Malaysia
  • Taiwan
  • Vietnam
  • Philippines
• Latin America
  • Brazil
  • Argentina
• MEA
  • Saudi Arabia
  • South Africa
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. Connectivity
  • 1.2.4. Distribution Channel
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. Connectivity outlook
  • 2.2.4. Distribution Channel outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. GLP-1 & CGM convergence Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. GLP-1 & CGM convergence Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. GLP-1 & CGM convergence Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. GLP-1 & CGM convergence Market: Product Movement Analysis
• 4.3. GLP-1 & CGM convergence Market by Product Outlook (USD Billion)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. Sensor
  • 4.5.1. Sensor Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.6. Applicator
  • 4.6.1. Applicator Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.7. Transmitter
  • 4.7.1. Transmitter Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 4.8. Device / Reader
  • 4.8.1. Device / Reader Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 5. GLP-1 & CGM convergence Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. GLP-1 & CGM convergence Market: Application Movement Analysis
• 5.3. GLP-1 & CGM convergence Market by Application Outlook (USD Billion)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Glucose / Diabetes Management
  • 5.5.1. Glucose / Diabetes Management Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.6. Lifestyle Monitoring
  • 5.6.1. Lifestyle Monitoring Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.7. Diet & Nutrition Monitoring
  • 5.7.1. Diet & Nutrition Monitoring Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.8. Physical Activity & Fitness Monitoring
  • 5.8.1. Physical Activity & Fitness Monitoring Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 5.9. Weight Management
  • 5.9.1. Weight Management Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 6. GLP-1 & CGM convergence Market: Connectivity Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. GLP-1 & CGM convergence Market: Connectivity Movement Analysis
• 6.3. GLP-1 & CGM convergence Market by Connectivity Outlook (USD Billion)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Bluetooth
  • 6.5.1. Bluetooth Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.6. 4G / Cellular
  • 6.6.1. 4G / Cellular Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 6.7. NFC
  • 6.7.1. NFC Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 7. GLP-1 & CGM convergence Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. GLP-1 & CGM convergence Market: Distribution Channel Movement Analysis
• 7.3. GLP-1 & CGM convergence Market by Distribution Channel Outlook (USD Billion)
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 7.5. Pharmacies
  • 7.5.1. Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.6. E-commerce
  • 7.6.1. E-commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.7. Others
  • 7.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. GLP-1 & CGM convergence Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Regional GLP-1 & CGM convergence Market Movement Analysis
• 8.3. GLP-1 & CGM convergence Market: Regional Estimates & Trend Analysis by Product & Source
• 8.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 8.5. North America
  • 8.5.1. North America GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.2. U.S.
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement scenario
    • 8.5.2.5. U.S. GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.3. Canada
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement scenario
    • 8.5.3.5. Canada GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.4. Mexico
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement scenario
    • 8.5.4.5. Mexico GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.5. Europe
  • 8.5.6. Europe GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.7. UK
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement scenario
    • 8.5.7.5. UK GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.8. Germany
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement scenario
    • 8.5.8.5. Germany GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.9. France
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Competitive Scenario
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement scenario
    • 8.5.9.5. France GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.10. Italy
    • 8.5.10.1. Key Country Dynamics
    • 8.5.10.2. Competitive Scenario
    • 8.5.10.3. Regulatory Framework
    • 8.5.10.4. Reimbursement scenario
    • 8.5.10.5. Italy GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.11. Spain
    • 8.5.11.1. Key Country Dynamics
    • 8.5.11.2. Competitive Scenario
    • 8.5.11.3. Regulatory Framework
    • 8.5.11.4. Reimbursement scenario
    • 8.5.11.5. Spain GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.12. Russia
    • 8.5.12.1. Key Country Dynamics
    • 8.5.12.2. Competitive Scenario
    • 8.5.12.3. Regulatory Framework
    • 8.5.12.4. Reimbursement scenario
    • 8.5.12.5. Russia GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.13. Denmark
    • 8.5.13.1. Key Country Dynamics
    • 8.5.13.2. Competitive Scenario
    • 8.5.13.3. Regulatory Framework
    • 8.5.13.4. Reimbursement scenario
    • 8.5.13.5. Denmark GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.14. Sweden
    • 8.5.14.1. Key Country Dynamics
    • 8.5.14.2. Competitive Scenario
    • 8.5.14.3. Regulatory Framework
    • 8.5.14.4. Reimbursement scenario
    • 8.5.14.5. Sweden GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.15. Norway
    • 8.5.15.1. Key Country Dynamics
    • 8.5.15.2. Competitive Scenario
    • 8.5.15.3. Regulatory Framework
    • 8.5.15.4. Reimbursement scenario
    • 8.5.15.5. Norway GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement scenario
    • 8.6.2.5. Japan GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement scenario
    • 8.6.3.5. China GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement scenario
    • 8.6.4.5. India GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.5. South Korea
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement scenario
    • 8.6.5.5. South Korea GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.6. Australia
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement scenario
    • 8.6.6.5. Australia GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Competitive Scenario
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement scenario
    • 8.6.7.5. Thailand GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.8. Singapore
    • 8.6.8.1. Key Country Dynamics
    • 8.6.8.2. Competitive Scenario
    • 8.6.8.3. Regulatory Framework
    • 8.6.8.4. Reimbursement scenario
    • 8.6.8.5. Singapore GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.9. Malaysia
    • 8.6.9.1. Key Country Dynamics
    • 8.6.9.2. Competitive Scenario
    • 8.6.9.3. Regulatory Framework
    • 8.6.9.4. Reimbursement scenario
    • 8.6.9.5. Malaysia GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.10. Taiwan
    • 8.6.10.1. Key Country Dynamics
    • 8.6.10.2. Competitive Scenario
    • 8.6.10.3. Regulatory Framework
    • 8.6.10.4. Reimbursement scenario
    • 8.6.10.5. Taiwan GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.11. Vietnam
    • 8.6.11.1. Key Country Dynamics
    • 8.6.11.2. Competitive Scenario
    • 8.6.11.3. Regulatory Framework
    • 8.6.11.4. Reimbursement scenario
    • 8.6.11.5. Vietnam GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.12. Philippines
    • 8.6.12.1. Key Country Dynamics
    • 8.6.12.2. Competitive Scenario
    • 8.6.12.3. Regulatory Framework
    • 8.6.12.4. Reimbursement scenario
    • 8.6.12.5. Philippines GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 8.7. Latin America
  • 8.7.1. Latin America GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement scenario
    • 8.7.2.5. Brazil GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement scenario
    • 8.7.3.5. Argentina GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 8.8. Middle East & Africa
  • 8.8.1. Middle East & Africa GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement scenario
    • 8.8.2.5. South Africa GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement scenario
    • 8.8.3.5. Saudi Arabia GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement scenario
    • 8.8.4.5. UAE GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Competitive Scenario
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement scenario
    • 8.8.5.5. Kuwait GLP-1 & CGM convergence Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Key Company Profiles
  • 9.2.1. Dexcom
    • 9.2.1.1. Company Overview
    • 9.2.1.2. Financial Performance
    • 9.2.1.3. Product Benchmarking
    • 9.2.1.4. Strategic Initiatives
  • 9.2.2. Abbott Laboratories
    • 9.2.2.1. Company Overview
    • 9.2.2.2. Financial Performance
    • 9.2.2.3. Product Benchmarking
    • 9.2.2.4. Strategic Initiatives
  • 9.2.3. Medtronic plc
    • 9.2.3.1. Company Overview
    • 9.2.3.2. Financial Performance
    • 9.2.3.3. Product Benchmarking
    • 9.2.3.4. Strategic Initiatives
  • 9.2.4. Sinocare, Inc. (iCan CGM)
    • 9.2.4.1. Company Overview
    • 9.2.4.2. Financial Performance
    • 9.2.4.3. Product Benchmarking
    • 9.2.4.4. Strategic Initiatives
  • 9.2.5. GlucoRx Limited (AiDEX, Vixxa)
    • 9.2.5.1. Company Overview
    • 9.2.5.2. Financial Performance
    • 9.2.5.3. Product Benchmarking
    • 9.2.5.4. Strategic Initiatives
  • 9.2.6. Bionime (RIGHTEST iFree CGM)
    • 9.2.6.1. Company Overview
    • 9.2.6.2. Financial Performance
    • 9.2.6.3. Product Benchmarking
    • 9.2.6.4. Strategic Initiatives
  • 9.2.7. Nemaura
    • 9.2.7.1. Company Overview
    • 9.2.7.2. Financial Performance
    • 9.2.7.3. Product Benchmarking
    • 9.2.7.4. Strategic Initiatives
  • 9.2.8. i-SENS, Inc.
    • 9.2.8.1. Company Overview
    • 9.2.8.2. Financial Performance
    • 9.2.8.3. Product Benchmarking
    • 9.2.8.4. Strategic Initiatives